Incyte Corporation

1.03 (1.67%)


Draw Mode:

Volume 1,760,372
Bid Price 61.71
Ask Price 66.90
News -
Day High 62.60


52 Week Range


Day Low 61.42
Company Name Stock Ticker Symbol Market Type
Incyte Corporation INCY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.03 1.67% 62.54 20:00:00
Open Price Low Price High Price Close Price Prev Close
61.50 61.42 62.60 62.54 61.51
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
26,299 1,760,372 $ 62.30 $ 109,679,514 - 60.71 - 86.29
Last Trade Time Type Quantity Stock Price Currency
16:57:30 formt 101 $ 62.54 USD

Incyte Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 13.95B 223.09M 219.51M $ 808.67M $ 242.60k 0.10 51.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 248.04k 15.10%

more financials information »

Incyte News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No INCY Message Board. Create One! See More Posts on INCY Message Board See More Message Board Posts

Historical INCY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week62.8763.0060.7161.742,259,580-0.33-0.52%
1 Month66.7567.722560.7163.721,685,238-4.21-6.31%
3 Months72.7576.0460.7169.851,717,242-10.21-14.03%
6 Months80.2886.2960.7175.671,651,040-17.74-22.1%
1 Year74.6886.2960.7174.851,522,936-12.14-16.26%
3 Years101.12111.0560.7178.191,461,191-38.58-38.15%
5 Years67.89111.0557.0077.921,463,803-5.35-7.88%

Incyte Description

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.